Supplementary Figure S2 from Baseline Mutations and ctDNA Dynamics as Prognostic and Predictive Factors in ER-Positive/HER2-Negative Metastatic Breast Cancer Patients
<p>Supplementary Figure 2. PFS analysis in baseline population (C1D1) on TP53 mutations, by treatment arms.</p>
Uloženo v:
| Hlavní autor: | |
|---|---|
| Další autoři: | , , , , , , , , , , , , , , , , , , , , , |
| Vydáno: |
2025
|
| Témata: | |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
|
| _version_ | 1849927631547400192 |
|---|---|
| author | Javier Pascual (15018176) |
| author2 | Miguel Gil-Gil (15052083) Paula Proszek (17141889) Christoph Zielinski (15054460) Alistair Reay (17141892) Manuel Ruiz-Borrego (15048425) Rosalind Cutts (17141895) Eva M. Ciruelos Gil (17141898) Andrew Feber (15124144) Montserrat Muñoz-Mateu (15054469) Claire Swift (17141901) Begoña Bermejo (15037896) Jesus Herranz (15048443) Mireia Margeli Vila (15054472) Antonio Antón (15054475) Zsuzsanna Kahan (17141904) Tibor Csöszi (17141907) Yuan Liu (15054484) Daniel Fernandez-Garcia (17141910) Isaac Garcia-Murillas (15018188) Michael Hubank (15104113) Nicholas C. Turner (17141913) Miguel Martín (15011399) |
| author2_role | author author author author author author author author author author author author author author author author author author author author author author |
| author_facet | Javier Pascual (15018176) Miguel Gil-Gil (15052083) Paula Proszek (17141889) Christoph Zielinski (15054460) Alistair Reay (17141892) Manuel Ruiz-Borrego (15048425) Rosalind Cutts (17141895) Eva M. Ciruelos Gil (17141898) Andrew Feber (15124144) Montserrat Muñoz-Mateu (15054469) Claire Swift (17141901) Begoña Bermejo (15037896) Jesus Herranz (15048443) Mireia Margeli Vila (15054472) Antonio Antón (15054475) Zsuzsanna Kahan (17141904) Tibor Csöszi (17141907) Yuan Liu (15054484) Daniel Fernandez-Garcia (17141910) Isaac Garcia-Murillas (15018188) Michael Hubank (15104113) Nicholas C. Turner (17141913) Miguel Martín (15011399) |
| author_role | author |
| dc.creator.none.fl_str_mv | Javier Pascual (15018176) Miguel Gil-Gil (15052083) Paula Proszek (17141889) Christoph Zielinski (15054460) Alistair Reay (17141892) Manuel Ruiz-Borrego (15048425) Rosalind Cutts (17141895) Eva M. Ciruelos Gil (17141898) Andrew Feber (15124144) Montserrat Muñoz-Mateu (15054469) Claire Swift (17141901) Begoña Bermejo (15037896) Jesus Herranz (15048443) Mireia Margeli Vila (15054472) Antonio Antón (15054475) Zsuzsanna Kahan (17141904) Tibor Csöszi (17141907) Yuan Liu (15054484) Daniel Fernandez-Garcia (17141910) Isaac Garcia-Murillas (15018188) Michael Hubank (15104113) Nicholas C. Turner (17141913) Miguel Martín (15011399) |
| dc.date.none.fl_str_mv | 2025-11-25T13:42:49Z |
| dc.identifier.none.fl_str_mv | 10.1158/1078-0432.30710216 |
| dc.relation.none.fl_str_mv | https://figshare.com/articles/figure/Supplementary_Figure_S2_from_Baseline_Mutations_and_ctDNA_Dynamics_as_Prognostic_and_Predictive_Factors_in_ER-Positive_HER2-Negative_Metastatic_Breast_Cancer_Patients/30710216 |
| dc.rights.none.fl_str_mv | CC BY info:eu-repo/semantics/openAccess |
| dc.subject.none.fl_str_mv | Cancer Cancer Detection and Diagnosis Therapeutic Research and Development Biomarkers Circulating tumor cells/DNA/exosomes Serum biomarkers Breast Cancer Translational Research |
| dc.title.none.fl_str_mv | Supplementary Figure S2 from Baseline Mutations and ctDNA Dynamics as Prognostic and Predictive Factors in ER-Positive/HER2-Negative Metastatic Breast Cancer Patients |
| dc.type.none.fl_str_mv | Image Figure info:eu-repo/semantics/publishedVersion image |
| description | <p>Supplementary Figure 2. PFS analysis in baseline population (C1D1) on TP53 mutations, by treatment arms.</p> |
| eu_rights_str_mv | openAccess |
| id | Manara_1f5e49a49406e48828ff8c50a9b809e0 |
| identifier_str_mv | 10.1158/1078-0432.30710216 |
| network_acronym_str | Manara |
| network_name_str | ManaraRepo |
| oai_identifier_str | oai:figshare.com:article/30710216 |
| publishDate | 2025 |
| repository.mail.fl_str_mv | |
| repository.name.fl_str_mv | |
| repository_id_str | |
| rights_invalid_str_mv | CC BY |
| spelling | Supplementary Figure S2 from Baseline Mutations and ctDNA Dynamics as Prognostic and Predictive Factors in ER-Positive/HER2-Negative Metastatic Breast Cancer PatientsJavier Pascual (15018176)Miguel Gil-Gil (15052083)Paula Proszek (17141889)Christoph Zielinski (15054460)Alistair Reay (17141892)Manuel Ruiz-Borrego (15048425)Rosalind Cutts (17141895)Eva M. Ciruelos Gil (17141898)Andrew Feber (15124144)Montserrat Muñoz-Mateu (15054469)Claire Swift (17141901)Begoña Bermejo (15037896)Jesus Herranz (15048443)Mireia Margeli Vila (15054472)Antonio Antón (15054475)Zsuzsanna Kahan (17141904)Tibor Csöszi (17141907)Yuan Liu (15054484)Daniel Fernandez-Garcia (17141910)Isaac Garcia-Murillas (15018188)Michael Hubank (15104113)Nicholas C. Turner (17141913)Miguel Martín (15011399)CancerCancer Detection and DiagnosisTherapeutic Research and DevelopmentBiomarkersCirculating tumor cells/DNA/exosomesSerum biomarkersBreast CancerTranslational Research<p>Supplementary Figure 2. PFS analysis in baseline population (C1D1) on TP53 mutations, by treatment arms.</p>2025-11-25T13:42:49ZImageFigureinfo:eu-repo/semantics/publishedVersionimage10.1158/1078-0432.30710216https://figshare.com/articles/figure/Supplementary_Figure_S2_from_Baseline_Mutations_and_ctDNA_Dynamics_as_Prognostic_and_Predictive_Factors_in_ER-Positive_HER2-Negative_Metastatic_Breast_Cancer_Patients/30710216CC BYinfo:eu-repo/semantics/openAccessoai:figshare.com:article/307102162025-11-25T13:42:49Z |
| spellingShingle | Supplementary Figure S2 from Baseline Mutations and ctDNA Dynamics as Prognostic and Predictive Factors in ER-Positive/HER2-Negative Metastatic Breast Cancer Patients Javier Pascual (15018176) Cancer Cancer Detection and Diagnosis Therapeutic Research and Development Biomarkers Circulating tumor cells/DNA/exosomes Serum biomarkers Breast Cancer Translational Research |
| status_str | publishedVersion |
| title | Supplementary Figure S2 from Baseline Mutations and ctDNA Dynamics as Prognostic and Predictive Factors in ER-Positive/HER2-Negative Metastatic Breast Cancer Patients |
| title_full | Supplementary Figure S2 from Baseline Mutations and ctDNA Dynamics as Prognostic and Predictive Factors in ER-Positive/HER2-Negative Metastatic Breast Cancer Patients |
| title_fullStr | Supplementary Figure S2 from Baseline Mutations and ctDNA Dynamics as Prognostic and Predictive Factors in ER-Positive/HER2-Negative Metastatic Breast Cancer Patients |
| title_full_unstemmed | Supplementary Figure S2 from Baseline Mutations and ctDNA Dynamics as Prognostic and Predictive Factors in ER-Positive/HER2-Negative Metastatic Breast Cancer Patients |
| title_short | Supplementary Figure S2 from Baseline Mutations and ctDNA Dynamics as Prognostic and Predictive Factors in ER-Positive/HER2-Negative Metastatic Breast Cancer Patients |
| title_sort | Supplementary Figure S2 from Baseline Mutations and ctDNA Dynamics as Prognostic and Predictive Factors in ER-Positive/HER2-Negative Metastatic Breast Cancer Patients |
| topic | Cancer Cancer Detection and Diagnosis Therapeutic Research and Development Biomarkers Circulating tumor cells/DNA/exosomes Serum biomarkers Breast Cancer Translational Research |